Susceptibility of to azithromycin and ceftriaxone in China: A retrospective study of national surveillance data from 2013 to 2016
In an observational study using data from the China Gonococcal Resistance Surveillance Programme, Yueping Yin estimate rates of reduced susceptibility to WHO-recommended antibiotics for Neisseria gonorrhoeae.
Vyšlo v časopise:
Susceptibility of to azithromycin and ceftriaxone in China: A retrospective study of national surveillance data from 2013 to 2016. PLoS Med 15(2): e32767. doi:10.1371/journal.pmed.1002499
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pmed.1002499
Souhrn
In an observational study using data from the China Gonococcal Resistance Surveillance Programme, Yueping Yin estimate rates of reduced susceptibility to WHO-recommended antibiotics for Neisseria gonorrhoeae.
Zdroje
1. Newman L, Rowley J, Vander Hoorn S, Wijesooriya NS, Unemo M, Low N, et al. Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. PLoS ONE. 2015;10:12:e0143304. doi: 10.1371/journal.pone.0143304 26646541
2. Yang S, Wu J, Ding C, Cui Y, Zhou Y, Li Y, et al. Epidemiological features of and changes in incidence of infectious diseases in China in the first decade after the SARS outbreak: an observational trend study. Lancet Infect Dis. 2017;17:716–25. doi: 10.1016/S1473-3099(17)30227-X 28412150
3. McCormack WM. Pelvic inflammatory disease. N Engl J Med. 1994;330:115–9. doi: 10.1056/NEJM199401133300207 8259168
4. Hook EW 3rd, Handsfield HH. Gonococcal infections in the adult. In: Holmes KK, Sparling PF, Mardh PA, Lemon SM, Stamm WE, Piot P, et al., editors. Sexually transmitted diseases. 3rd ed. New York: McGraw-Hill; 1999. pp. 451–66.
5. Cohen MS, Hoffman IF, Royce RA, Kazembe P, Dyer JR, Daly CC, et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Research Group. Lancet. 1997;349:1868–73. 9217758
6. Unemo M, Shafer WM. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future. Clin Microbiol Rev. 2014;27:587–613. doi: 10.1128/CMR.00010-14 24982323
7. Shimuta K, Unemo M, Nakayama S, Morita-Ishihara T, Dorin M, Kawahata T, et al. Antimicrobial resistance and molecular typing of Neisseria gonorrhoeae isolates in Kyoto and Osaka, Japan, 2010 to 2012: intensified surveillance after identification of the first strain (H041) with high-level ceftriaxone resistance. Antimicrob Agents Chemother. 2013;57:5225–32. doi: 10.1128/AAC.01295-13 23939890
8. Ison CA, Hussey J, Sankar KN, Evans J, Alexander S. Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. Euro Surveill. 2011;16:19833. 21492528
9. Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64(RR-03):1–137. 26042815
10. Bignell C, Unemo M, European STI Guidelines Editorial Board. 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS. 2013;24:85–92. doi: 10.1177/0956462412472837 24400344
11. World Health Organization. WHO guidelines for the treatment of Neisseria gonorrhoeae. Geneva: World Health Organization; 2016.
12. Fifer H, Natarajan U, Jones L, Alexander S, Hughes G, Golparian D, et al. Failure of dual antimicrobial therapy in treatment of gonorrhea. N Engl J Med. 2016;374:2504–6. doi: 10.1056/NEJMc1512757 27332921
13. World Health Organization. Manual for the laboratory identification and antimicrobial susceptibility testing of bacterial pathogens of public health concern in the developing world. Geneva: World Health Organization; 2003.
14. Ye S, Su X, Wang Q, Yin Y, Dai X, Sun H. Surveillance of antibiotic resistance of Neisseria gonorrhoeae isolates in China, 1993–1998. Sex Transm Dis. 2002;29:242–5. 11912467
15. US Centers for Disease Control and Prevention. Gonococcal Isolate Surveillance Project (GISP) protocol. Atlanta: US Centers for Disease Control and Prevention; 2016.
16. Gong XD, Yue XL, Jiang N, Teng F, Meng PX, Li J, et al. Epidemiological characteristics and trends of gonorrhea in China from 2000 to 2014. Chin J Dermatol. 2015;48:301–6.
17. US Centers for Disease Control and Prevention Division of STD Prevention. Sexually transmitted disease surveillance 2014: Gonococcal Isolate Surveillance Project (GISP) supplement and profiles. Atlanta: US Centers for Disease Control and Prevention; 2016.
18. Martin I, Sawatzky P, Liu G, Allen V, Lefebvre B, Hoang L, et al. Decline in decreased cephalosporin susceptibility and increase in azithromycin resistance in Neisseria gonorrhoeae, Canada. Emerg Infect Dis. 2016;22:65–7. doi: 10.3201/eid2201.151247 26689114
19. Cole MJ, Spiteri G, Jacobsson S, Pitt R, Grigorjev V, Unemo M, et al. Is the tide turning again for cephalosporin resistance in Neisseria gonorrhoeae in Europe? Results from the 2013 European surveillance. BMC Infect Dis. 2015;15:321. doi: 10.1186/s12879-015-1013-x 26259560
20. European Centre for Disease Prevention and Control. Gonococcal antimicrobial susceptibility surveillance in Europe, 2014. Stockholm: European Centre for Disease Prevention and Control; 2016.
21. Public Health England. Surveillance of antimicrobial resistance in Neisseria gonorrhoeae—key findings from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP). London: Public Health England; 2016.
22. Regnath T, Mertes T, Ignatius R. Antimicrobial resistance of Neisseria gonorrhoeae isolates in south-west Germany, 2004 to 2015: increasing minimal inhibitory concentrations of tetracycline but no resistance to third-generation cephalosporins. Euro Surveill. 2016;21:30335.
23. Lahra MM, Australian Gonococcal Surveillance Programme. Australian Gonococcal Surveillance Programme annual report, 2013. Commun Dis Intell Q Rep. 2015;39:E137–45. 26063087
24. Lahra MM, Australian Gonococcal Surveillance Programme. Australian Gonococcal Surveillance Programme annual report, 2014. Commun Dis Intell Q Rep. 2015;39:E347–54. 26620348
25. Lahra MM, Enriquez RP, National Neisseria Network. Australian Gonococcal Surveillance Programme annual report, 2015. Commun Dis Intell Q Rep. 2017;41:E60–7.
26. Latif AS, Gwanzura L, Machiha A, Ndowa F, Tarupiwa A, Gudza-Mugabe M, et al. Antimicrobial susceptibility in Neisseria gonorrhoeae isolates from five sentinel surveillance sites in Zimbabwe, 2015–2016. Sex Transm Infect. 2017 May 5. doi: 10.1136/sextrans-2016-053090 28476914
27. Yasuda M, Hatazaki K, Ito S, Kitanohara M, Yoh M, Kojima M, et al. Antimicrobial susceptibility of Neisseria gonorrhoeae in Japan from 2000 to 2015. Sex Transm Dis. 2017;44:149–53. doi: 10.1097/OLQ.0000000000000556 28178112
28. Tapsall J. Neisseria gonorrhoeae and emerging resistance to extended spectrum cephalosporins. Curr Opin Infect Dis 2009;22:87–91. doi: 10.1097/QCO.0b013e328320a836 19532086
29. Centers for Disease Control and Prevention (CDC). Cephalosporin susceptibility among Neisseria gonorrhoeae isolates—United States, 2000–2010. MMWR Morb Mortal Wkly Rep. 2011;60:873–7. 21734634
30. Wang QQ, Liu QZ, Xu JH. Guidelines of sexually transmitted disease prevention and treatment. Shanghai: Shanghai Science and Technology Publishing House; 2014.
31. Su S, Chow EP, Muessig KE, Yuan L, Tucker JD, Zhang X, et al. Sustained high prevalence of viral hepatitis and sexually transmissible infections among female sex workers in China: a systematic review and meta-analysis. BMC Infect Dis. 2016;16:2. doi: 10.1186/s12879-015-1322-0 26732281
32. Chen XS, Yin YP, Liang GJ, Wang QQ, Jiang N, Liu Q, et al. The prevalences of Neisseria gonorrhoeae and Chlamydia trachomatis infections among female sex workers in China. BMC Public Health. 2013;13:121. doi: 10.1186/1471-2458-13-121 23390952
33. Fu GF, Jiang N, Hu HY, Mahapatra T, Yin YP, Mahapatra S, et al. The epidemic of HIV, syphilis, chlamydia and gonorrhea and the correlates of sexual transmitted infections among men who have sex with men in Jiangsu, China, 2009. PLoS ONE. 2015;10:3:e0118863. doi: 10.1371/journal.pone.0118863 25775451
34. Parish WL, Laumann EO, Cohen MS, Pan S, Zheng H, Hoffman I, et al. Population-based study of chlamydial infection in China: a hidden epidemic. JAMA. 2003;289:1265–73. 12633188
35. Unemo M1, Shafer WM. Antibiotic resistance in Neisseria gonorrhoeae: origin, evolution, and lessons learned for the future. Ann N Y Acad Sci. 2011;1230:E19–28. doi: 10.1111/j.1749-6632.2011.06215.x 22239555
36. Yin X, Song F, Gong Y, Tu X, Wang Y, Cao S, et al. A systematic review of antibiotic utilization in China. J Antimicrob Chemother. 2013;68:2445–52. doi: 10.1093/jac/dkt223 23800903
37. Wang J, Wang P, Wang X, Zheng Y, Xiao Y. Use and prescription of antibiotics in primary health care settings in China. JAMA Intern Med. 2014;174:1914–20. doi: 10.1001/jamainternmed.2014.5214 25285394
38. Trecker MA, Waldner C, Jolly A, Liao M, Gu W, Dillon JA. Behavioral and socioeconomic risk factors associated with probable resistance to ceftriaxone and resistance to penicillin and tetracycline in Neisseria gonorrhoeae in Shanghai. PLoS ONE. 2014;9:2:e89458. doi: 10.1371/journal.pone.0089458 24586792
39. Cole MJ, Spiteri G, Town K, Unemo M, Hoffmann S, Chisholm SA, et al. Risk factors for antimicrobial resistant Neisseria gonorrhoeae in Europe. Sex Transm Infect. 2014;41:723–9.
40. Goldstein E, Kirkcaldy RD, Reshef D, Berman S, Weinstock H, Sabeti P, et al. Factors related to increasing prevalence of resistance to ciprofloxacin and other antimicrobial drugs in Neisseria gonorrhoeae, United States. Emerg Infect Dis. 2012;18:1290–7. doi: 10.3201/eid1808.111202 22840274
41. Wind CM, Schim van der Loeff MF, van Dam AP, de Vries HJ, van der Helm JJ. Trends in antimicrobial susceptibility for azithromycin and ceftriaxone in Neisseria gonorrhoeae isolates in Amsterdam, the Netherlands, between 2012 and 2015. Euro Surveill. 2017;22:30431. doi: 10.2807/1560-7917.ES.2017.22.1.30431 28079519
42. Bissessor M, Whiley DM, Lee DM, Snow AF, Fairley CK, Peel J, et al. Detection of Neisseria gonorrhoeae isolates from tonsils and posterior oropharynx. J Clin Microbiol. 2015;53:3624–6. doi: 10.1128/JCM.01647-15 26292303
43. Chen SC, Yin YP, Dai XQ, Unemo M, Chen XS. First nationwide study regarding ceftriaxone resistance and molecular epidemiology of Neisseria gonorrhoeae in China. J Antimicrob Chemother. 2016;71:92–9. doi: 10.1093/jac/dkv321 26472770
44. De Silva D, Peters J, Cole K, Cole MJ, Cresswell F, Dean G, et al. Whole-genome sequencing to determine transmission of Neisseria gonorrhoeae: an observational study. Lancet Infect Dis. 2016;16:1295–303. doi: 10.1016/S1473-3099(16)30157-8 27427203
Štítky
Interné lekárstvoČlánok vyšiel v časopise
PLOS Medicine
2018 Číslo 2
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
- Pleiotropní účinky statinů na kardiovaskulární systém
- Statiny indukovaná myopatie: Jak na diferenciální diagnostiku?
- Zástava srdce u pacienta se střelnými ranami – kazuistika
- Statinová intolerance
Najčítanejšie v tomto čísle
- The potential impact of case-area targeted interventions in response to cholera outbreaks: A modeling study
- Susceptibility of to azithromycin and ceftriaxone in China: A retrospective study of national surveillance data from 2013 to 2016
- Prevalence of sexually transmitted infections among young people in South Africa: A nested survey in a health and demographic surveillance site
- Diet during pregnancy and infancy and risk of allergic or autoimmune disease: A systematic review and meta-analysis